探索临床试验情境中的实施结局:对医生试验利益相关者的定性研究
该定性研究从单一机构目的性选取15名癌症临床试验医生利益相关者进行半结构化访谈,探讨其对改编自Proctor实施结局框架的试验情境实施结局的感知与应用。结果显示这些实施结局被良好理解且适用(即适当且可接受),试验可行性与实施成本被认为对试验设计与实施最关键,试验渗透度最难测量,试验改进与实施评估的正式方法发展不佳。
要点
- 癌症临床试验医生利益相关者理解并认可改编的实施结局框架适用于试验情境。
- 试验可行性与实施成本被认为对试验设计与实施最为关键。
- 试验渗透度因合格患者识别问题而最难测量,试验改进的正式方法发展不佳。
核心结论
- 改编至试验情境的实施结局对癌症临床试验医生利益相关者而言可接受且适当,使用这些结局可促进临床试验改进干预的评估与设计,并突出开发新工具(如信息学解决方案)的潜在领域。
研究设计与样本
- 定性研究,从单一机构目的性选取15名代表不同专科、试验角色和试验申办方类型的癌症临床试验医生利益相关者进行半结构化访谈。
主要发现
- 实施结局被良好理解且适用(即适当且可接受)于临床试验利益相关者。
- 试验可行性与实施成本被认为对试验设计与实施最为关键。
- 试验渗透度最难测量,主要因合格患者识别困难。
- 试验改进与试验实施评估的正式方法发展不佳。
- 癌症临床试验医生利益相关者提及一些用于改进试验的设计与实施技术,但很少被正式评估或基于理论。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cancer clinical trials can be considered evidence-based interventions with substantial benefits, but suffer from poor implementation leading to low enrollment and frequent failure. Applying implementation science approaches such as outcomes frameworks to the trial context could aid in contextualizing and evaluating trial improvement strategies. However, the acceptability and appropriateness of these adapted outcomes to trial stakeholders are unclear. For these reasons, we interviewed cancer clinical trial physician stakeholders to explore how they perceive and address clinical trial implementation outcomes. METHODS: We purposively selected 15 cancer clinical trial physician stakeholders from our institution representing different specialties, trial roles, and trial sponsor types. We performed semi-structured interviews to explore a previous adaptation of Proctor's Implementation Outcomes Framework to the clinical trial context. Emergent themes from each outcome were developed. RESULTS: The implementation outcomes were well understood and applicable (i.e., appropriate and acceptable) to clinical trial stakeholders. We describe cancer clinical trial physician stakeholder understanding of these outcomes and current application of these concepts. Trial feasibility and implementation cost were felt to be most critical to trial design and implementation. Trial penetration was most difficult to measure, primarily due to eligible patient identification. In general, we found that formal methods for trial improvement and trial implementation evaluation were poorly developed. Cancer clinical trial physician stakeholders referred to some design and implementation techniques used to improve trials, but these were infrequently formally evaluated or theory-based. CONCLUSION: Implementation outcomes adapted to the trial context were acceptable and appropriate to cancer clinical trial physician stakeholders. Use of these outcomes could facilitate the evaluation and design of clinical trial improvement interventions. Additionally, these outcomes highlight potential areas for the development of new tools, for example informatics solutions, to improve the evaluation and implementation of clinical trials.
引用
- Stensland KD, Sales AE, Vedapudi VK, et al. Exploring implementation outcomes in the clinical trial context: a qualitative study of physician trial stakeholders. Trials. 2023. PMID: 37106368. doi:10.1186/s13063-023-07304-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。